Active ingredient
Doxorubicin
64 finished FDA listings contain Doxorubicin as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE
- Dosage forms
- Injectable, Liposomal, Injection, Powder, Lyophilized, For Solution, Injection, Solution, Injection, Suspension, Liposomal
- Routes
- Intravenous, Intravitreal
- Manufacturers / labelers
- 19
- Strengths listed
- 2 mg/ml
- Brand names in FDA listings
- Doxil, Doxorubicin Hydrochloride, Doxorubicin Hydrochloride Liposome, Doxorubicin Hydrochloride, Liposomal
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 3639
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| NDA 050629 | PFIZER | 1987-12-23 | 10 |
| ANDA 062921 | HIKMA | 1989-03-17 | 2 |
| ANDA 062975 | HIKMA | 1989-03-17 | 6 |
| ANDA 064097 | HIKMA | 1994-09-13 | 2 |
| ANDA 063277 | FRESENIUS KABI USA | 1995-10-26 | 2 |
| NDA 050718 | BAXTER HLTHCARE CORP | 1995-11-17 | 6 |
| ANDA 200170 | MYLAN LABS LTD | 2011-10-28 | 1 |
| ANDA 091418 | SUN PHARM INDS | 2012-02-15 | 2 |
| ANDA 203263 | SUN PHARM | 2013-02-04 | 6 |
| ANDA 203622 | ACTAVIS INC | 2014-06-27 | 1 |
| ANDA 208888 | AMNEAL | 2017-02-17 | 2 |
| ANDA 208657 | DR REDDYS | 2017-05-15 | 1 |
| ANDA 209825 | GLAND | 2017-08-11 | 4 |
| ANDA 212299 | ZYDUS LIFESCIENCES | 2020-09-10 | 6 |
| ANDA 215178 | LUPIN | 2024-07-16 | 3 |
| ANDA 219199 | ALEMBIC | 2025-06-27 | 8 |
| ANDA 219881 | QILU PHARM HAINAN | 2026-02-03 | 1 |
Official labeling on DailyMed
- DOXORUBICIN HYDROCHLORIDE INJECTION, SUSPENSION, LIPOSOMAL [DR. REDDY'S LABORATORIES INC.] · version 2 · 2026-09-24
- DOXORUBICIN HYDROCHLORIDE INJECTION, SUSPENSION, LIPOSOMAL [BLUEPOINT LABORATORIES] · version 1 · 2026-07-13
- DOXIL (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [BAXTER HEALTHCARE COMPANY] · version 13 · 2026-06-03
- DOXORUBICIN HYDROCHLORIDE INJECTABLE, LIPOSOMAL [BLUEPOINT LABORATORIES] · version 5 · 2026-05-25
- DOXORUBICIN HYDROCHLORIDE INJECTION, SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] · version 28 · 2026-05-07
- DOXORUBICIN HYDROCHLORIDE INJECTION, SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] · version 14 · 2026-05-01
- DOXORUBICIN HYDROCHLORIDE INJECTABLE, LIPOSOMAL [NORTHSTAR RXLLC] · version 8 · 2026-04-14
- DOXORUBICIN HYDROCHLORIDE INJECTABLE, LIPOSOMAL [SUN PHARMACEUTICAL INDUSTRIES, INC.] · version 24 · 2026-04-09
- DOXORUBICIN HYDROCHLORIDE INJECTABLE, LIPOSOMAL [BLUEPOINT LABORATORIES] · version 1 · 2026-04-02
- DOXORUBICIN HYDROCHLORIDE INJECTABLE, LIPOSOMAL [ZYDUS PHARMACEUTICALS USA INC.] · version 5 · 2026-03-27
- DOXIL (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [BAXTER HEALTHCARE CORPORATION] · version 5 · 2026-03-18
- DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE) INJECTION, SUSPENSION, LIPOSOMAL [SAGENT PHARMACEUTICALS] · version 1 · 2026-03-04
Showing the 12 most recent of 30 labels.
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.